209 related articles for article (PubMed ID: 11574892)
1. DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates.
Mondal N; Parvin JD
Nature; 2001 Sep; 413(6854):435-8. PubMed ID: 11574892
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
3. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity.
Mondal N; Zhang Y; Jonsson Z; Dhar SK; Kannapiran M; Parvin JD
Nucleic Acids Res; 2003 Sep; 31(17):5016-24. PubMed ID: 12930951
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
5. Identification of nucleophosmin/B23, an acidic nucleolar protein, as a stimulatory factor for in vitro replication of adenovirus DNA complexed with viral basic core proteins.
Okuwaki M; Iwamatsu A; Tsujimoto M; Nagata K
J Mol Biol; 2001 Aug; 311(1):41-55. PubMed ID: 11469856
[TBL] [Abstract][Full Text] [Related]
6. Synergistic functions of SII and p300 in productive activator-dependent transcription of chromatin templates.
Guermah M; Palhan VB; Tackett AJ; Chait BT; Roeder RG
Cell; 2006 Apr; 125(2):275-86. PubMed ID: 16630816
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
8. Three transitions in the RNA polymerase II transcription complex during initiation.
Holstege FC; Fiedler U; Timmers HT
EMBO J; 1997 Dec; 16(24):7468-80. PubMed ID: 9405375
[TBL] [Abstract][Full Text] [Related]
9. Assembly of transcriptionally active chromatin in vitro: a possible role for topoisomerase II.
To RQ; Kmiec EB
Cell Growth Differ; 1990 Jan; 1(1):39-45. PubMed ID: 1964075
[TBL] [Abstract][Full Text] [Related]
10. Nature of the nucleosomal barrier to RNA polymerase II.
Kireeva ML; Hancock B; Cremona GH; Walter W; Studitsky VM; Kashlev M
Mol Cell; 2005 Apr; 18(1):97-108. PubMed ID: 15808512
[TBL] [Abstract][Full Text] [Related]
11. Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo.
Saunders A; Werner J; Andrulis ED; Nakayama T; Hirose S; Reinberg D; Lis JT
Science; 2003 Aug; 301(5636):1094-6. PubMed ID: 12934007
[TBL] [Abstract][Full Text] [Related]
12. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
Sakaguchi A; Kikuchi A
J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
Lok CN; Lang AJ; Mirski SE; Cole SP
Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
[TBL] [Abstract][Full Text] [Related]
14. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells.
Khobta A; Ferri F; Lotito L; Montecucco A; Rossi R; Capranico G
J Mol Biol; 2006 Mar; 357(1):127-38. PubMed ID: 16427078
[TBL] [Abstract][Full Text] [Related]
15. ICRF-193, an inhibitor of topoisomerase II, demonstrates that DNA replication in sperm nuclei reconstituted in Xenopus egg extracts does not require chromatin decondensation.
Takasuga Y; Andoh T; Yamashita J; Yagura T
Exp Cell Res; 1995 Apr; 217(2):378-84. PubMed ID: 7698239
[TBL] [Abstract][Full Text] [Related]
16. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis delta antigen binds to the clamp of RNA polymerase II and affects transcriptional fidelity.
Yamaguchi Y; Mura T; Chanarat S; Okamoto S; Handa H
Genes Cells; 2007 Jul; 12(7):863-75. PubMed ID: 17584298
[TBL] [Abstract][Full Text] [Related]
18. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
Gray MD; Mann M; Nitiss JL; Hendershot LM
Mol Pharmacol; 2005 Dec; 68(6):1699-707. PubMed ID: 16141312
[TBL] [Abstract][Full Text] [Related]
19. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH
Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580
[TBL] [Abstract][Full Text] [Related]
20. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
